David Campbell

Prof. David Campbell

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2009 in Molecular and Cellular Biology
Verified
Journal Article
Open access
PDF file
JZJesse R. Zamudio
Jesse R. Zamudio
BMBidyottam Mittra
Bidyottam Mittra
ACArnab Chattopadhyay
Arnab Chattopadhyay
JWJames Wohlschlegel
James Wohlschlegel
NSNancy R. Sturm
Nancy R. Sturm
DCDavid Campbell
David Campbell
Kinetoplastid flagellates attach a 39-nucleotide spliced leader (SL) upstream of protein-coding regions in polycistronic RNA precursors through trans splicing. SL modifications include cap 2′-O-ribose methylation of the first four nucleotides and pseudouridine (ψ) formation at uracil 28. In Trypanosoma brucei, TbMTr1 performs 2′-O-ribose methylation of the first transcribed nucleotide, or cap 1. We report the characterization of an SL RNA processing complex with TbMTr1 and the SLA1 H/ACA small nucleolar ribonucleoprotein (snoRNP) particle that guides SL ψ28 formation. TbMTr1 is in a high-molecular-weight complex containing the four conserved core proteins of H/ACA snoRNPs, a kinetoplastid-specific protein designated methyltransferase-associated protein (TbMTAP), and the SLA1 snoRNA. TbMTAP-null lines are viable but have decreased SL RNA processing efficiency in cap methylation, 3′-end maturation, and ψ28 formation. TbMTAP is required for association between TbMTr1 and the SLA1 snoRNP but does not affect U1 small nuclear RNA methylation. A complex methylation profile in the mRNA population of TbMTAP-null lines indicates an additional effect on cap 4 methylations. The TbMTr1 complex specializes the SLA1 H/ACA snoRNP for efficient processing of multiple modifications on the SL RNA substrate.


1 February 2012 in Antiviral Therapy
Verified
Journal Article
Open access
DHDaphne M Hotho
Daphne M Hotho
JBJoep de Bruijne
Joep de Bruijne
AOA Marie O'FArrell
A Marie O'FArrell
TBTeresa Boyea
Teresa Boyea
JLJianke Li
Jianke Li
HRHendrik W Reesink
Hendrik W Reesink
Background: PHX1766 is a novel HCV NS3/4 protease inhibitor with robust potency and high selectivity in replicon studies (50% maximal effective concentration 8 nM). Two clinical trials investigated the safety, tolerability, pharmacokinetics and antiviral activity of PHX1766 in healthy volunteers (HV) and chronic hepatitis C patients, by use of a dose-adaptive overlapping clinical trial design. Methods: Two randomized, double-blind, placebo-controlled clinical trials were conducted. Single doses of PHX1766 or placebo were administered to 25 HV and six HCV genotype 1-infected patients (50 mg once daily –1,000 mg once daily, 250 mg twice daily and 100 mg of a new formulation of PHX1766 once daily). Multiple doses of PHX1766 or placebo were administered to 32 HV and seven HCV genotype 1-infected patients (50 mg once daily –800 mg twice daily). Results: Oral administration of PHX1766 was safe and well tolerated at all dose levels with rapid absorption (time at which concentration maximum is reached of 1–4 h) and with mean terminal half-lives of 4–23 h. Multiple doses of PHX1766 800 mg twice daily in HCV patients produced an area under the plasma concentration–time curve from time of drug administration to the last time point with a measurable concentration after dosing accumulation ratio of 2.3. The mean maximal observed HCV RNA decline was 0.6 log 10 IU/ml in the first 24 h in the single-dose protocol and 1.5 log 10 IU/ml after 6 days of PHX1766 dosing. Conclusions: An overlapping, dose-adaptive single-dose and multiple-dose escalating design in HV and HCV-infected patients proved to be highly efficient in identifying a therapeutic dose. Although in vitro replicon studies indicated a robust HCV RNA viral decline of PHX1766, the study in HCV patients demonstrated only modest viral load reduction.

9 March 2021 in Metabolites
Verified
Journal Article
Open access
PDF file
RWRoy Chih Chung Wang
Roy Chih Chung Wang
DCDavid Campbell
David Campbell
JGJames Robert Green
James Robert Green
MCMiroslava Cuperlovic-Culf
Miroslava Cuperlovic-Culf
High-throughput metabolomics can be used to optimize cell growth for enhanced production or for monitoring cell health in bioreactors. It has applications in cell and gene therapies, vaccines, biologics, and bioprocessing. NMR metabolomics is a method that allows for fast and reliable experimentation, requires only minimal sample preparation, and can be set up to take online measurements of cell media for bioreactor monitoring. This type of application requires a fully automated metabolite quantification method that can be linked with high-throughput measurements. In this review, we discuss the quantifier requirements in this type of application, the existing methods for NMR metabolomics quantification, and the performance of three existing quantifiers in the context of NMR metabolomics for bioreactor monitoring.

28 September 2019 in Statistics and Computing
Verified
Journal Article
Closed access
PDF file
OCOksana A. Chkrebtii
Oksana A. Chkrebtii
DCDavid Campbell
David Campbell

1 July 2004 in FEMS Microbiology Letters
Verified
Journal Article
Open access
PDF file
RHRobert A Hitchcock
Robert A Hitchcock
GZGusti M. Zeiner
Gusti M. Zeiner
NSNancy R. Sturm
Nancy R. Sturm
DCDavid Campbell
David Campbell
Post-transcriptional 3′ end formation is an essential step in the maturation of most small RNAs. Knowledge of the precise 3′ ends of mature RNAs is e